Elliptinium: Phase II study in advanced measurable breast cancer

Joseph Treat; Andrew Greenspan; Aquilur Rahman; Mary S. McCabe; Patrick J. Byrne

doi:10.1007/BF00170864

Elliptinium: Phase II study in advanced measurable breast cancer

Joseph Treat, Andrew Greenspan, Aquilur Rahman, Mary S. McCabe, Patrick J. Byrne

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m² × 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.

Original language	English
Pages (from-to)	231-234
Number of pages	4
Journal	Investigational New Drugs
Volume	7
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00170864
State	Published - Jul 1989

Keywords

Phase II study
breast cancer
elliptinium

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00170864

Cite this

@article{d3b3dc7521dc4d22bb18f2e34a5dc5a4,

title = "Elliptinium: Phase II study in advanced measurable breast cancer",

abstract = "Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m2 × 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.",

keywords = "Phase II study, breast cancer, elliptinium",

author = "Joseph Treat and Andrew Greenspan and Aquilur Rahman and McCabe, {Mary S.} and Byrne, {Patrick J.}",

year = "1989",

month = jul,

doi = "10.1007/BF00170864",

language = "English",

volume = "7",

pages = "231--234",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2-3",

}

TY - JOUR

T1 - Elliptinium

T2 - Phase II study in advanced measurable breast cancer

AU - Treat, Joseph

AU - Greenspan, Andrew

AU - Rahman, Aquilur

AU - McCabe, Mary S.

AU - Byrne, Patrick J.

PY - 1989/7

Y1 - 1989/7

N2 - Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m2 × 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.

AB - Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m2 × 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.

KW - Phase II study

KW - breast cancer

KW - elliptinium

UR - http://www.scopus.com/inward/record.url?scp=0024315048&partnerID=8YFLogxK

U2 - 10.1007/BF00170864

DO - 10.1007/BF00170864

M3 - Article

C2 - 2793378

AN - SCOPUS:0024315048

SN - 0167-6997

VL - 7

SP - 231

EP - 234

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2-3

ER -

Elliptinium: Phase II study in advanced measurable breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this